Crossmark

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response

Published Online: 2021-09-08

Published Print: 2021-12

Authors

Park, Jeong A.

Wang, Linlin

Cheung, Nai-Kong V. http://orcid.org/0000-0001-6323-5171
Funding

Funding for this research was provided by:

enid a. haupt endowed chair

robert steel foundation,

kids walk for kids with cancer

national cancer institute (P30 CA008748)
License Information

Text and Data Mining valid from 2021-09-08

Version of Record valid from 2021-09-08
More Information

Article History

Received: 24 June 2021

Accepted: 30 August 2021

First Online: 8 September 2021

Declarations

:

: All animal experiments were approved by the Memorial Sloan Kettering’s Institutional Animal Care and Use Committee (IACUC) and were executed according to the ACUC guidelines. Patient-derived tumor xenografts were established with MSKCC IRB approval.

: Not applicable.

: NKC reports past commercial research grants from Y-mAbs Therapeutics for hu3F8, 8H9, bispecific antibodies for CD33 and GD2, and a grant for SADA technology transfer; NKC has ownership interest/equity in Y-mAbs Therapeutics Inc., Abpro-Labs, and Eureka Therapeutics. NKC is the inventor and owner of issued patents licensed by MSK to Y-mAbs Therapeutics, Biotec Pharmacon, and Abpro-labs. Hu3F8, 8H9, bispecific antibodies against CD33 and GD2 were licensed by MSK to Y-mAbs Therapeutics. NKC is an advisory board member of Eureka Therapeutics. MSK has financial interest in Y-mabs. JP has no disclosures to report.

Document is current